SEATTLE, Oct. 07, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global immunomodulators market is estimated to be valued at US$ 91850.0 Million in 2021 and is expected to exhibit a CAGR of 7.9% over the forecast period (2021-2028).
Key Trends and Analysis of the Global Immunomodulators Market:
The key players are actively investing in research and development (R&D) of drugs for the treatment of autoimmune disorders due to their huge demand worldwide, which is propelling the growth of global immunomodulators market.
For instance, in December 2020, TG Therapeutics a commercial stage biopharmaceutical company, announced positive topline results from the Phase III ULTIMATE I & II studies evaluating ublituximab monotherapy for the treatment of multiple sclerosis patients.
Furthermore, key players operating in the immunomodulators market are focusing on adoption of inorganic growth strategies such as acquisition and collaboration to increase their market presence in the global market.
Request for Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4609
For instance, Cleveland BioLabs, Inc. and Cytocom, Inc. signed a merger agreement in October 2020 to combine their operations in a single deal. For Cleveland and Cytocom shareholders, this merger will change the growth possibilities. It will also enhance their positions and speed up their ability to use immune-modulating drugs to treat major medical diseases.
Key Market Takeaways:
The global immunomodulators market is expected to exhibit a CAGR of 7.9% during the forecast period, owing to the increasing approval of drugs by key players for the treatment of autoimmune diseases. For instance, in October 2018, Amgen announced that AMGEVITATM, a biosimilar to adalimumab, will be available in European countries. The European Commission has authorized AMGEVITA as the first biosimilar of adalimumab (EC). AMGEVITA is approved for the treatment of inflammatory illnesses in humans, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis, and other inflammatory conditions.
Among application, others segment, including, multiple sclerosis, crohn's disease, rheumatoid arthritis, and others, holds a dominant share in the market owing to the widespread use of Immunomodulators for treatment purposes. Furthermore, significant untapped prospects, as well as new medication development projects in response to unmet needs and planned product launches for a variety of indications, are paving the way for future growth.
Competitive Landscape:
Key players operating in the global immunomodulators market include F. Hoffmann-La Roche Ltd., Biogen Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Amgen, Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Eli Lilly and Company, Abbott Laboratories, Johnson & Johnson, and Pfizer Inc.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4609
Market Segmentation:
- Global Immunomodulators Market, By Product Type:
- Immunosuppressants
- Calcineurin Inhibitors
- Glucocorticoids
- Antimetabolites
- Others
- Immunostimulants
- Vaccines
- Antibodies
- Others
- Immunosuppressants
- Global Immunomodulators Market, By Application:
- Oncology
- Respiratory
- HIV
- Others
- Global Immunomodulators Market, By End User:
- Hospitals
- Clinics
- Others
- Global Immunomodulators Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- North America
-
- Asia Pacific
-
-
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
-
-
- Middle East
-
-
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
-
-
- Africa
-
-
- By Region/Country
- South Africa
- Central Africa
- North Africa
- By Region/Country
-
Related Market Intelligence Reports:
Multiple Myeloma Drugs Market By Drug Type (Immunomodulating agents, Proteasome Inhibitors, Histone Deacetylase (HDAC) Inhibitors, Corticosteroids, Monoclonal Antibodies), By Distribtuion Channel (Hospital Pharmacy, Retail Pharmacy, ePharmacies) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
Cancer Biologics Market, by Product (Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, and Immune Checkpoint Inhibitors), by Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, and Others), by Distribution Channel (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Immuno Oncology Assays Market, by Product Type (Consumables, Software), By Technology (Next generation sequencing, Flow cytometry ,PCR, and others), By Indication (Lung Cancer, Colorectal Cancer, Melanoma, Leukemia ,Lymphoma ,Multiple Myeloma, Bladder Cancer , and Others), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) -Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
